Progyny, Inc. (NASDAQ:PGNY) Position Reduced by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lowered its stake in Progyny, Inc. (NASDAQ:PGNY) by 68.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 715 shares of the company’s stock after selling 1,520 shares during the period. Nisa Investment Advisors LLC’s holdings in Progyny were worth $27,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. RiverPark Advisors LLC increased its holdings in Progyny by 54.0% in the fourth quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock valued at $40,000 after buying an additional 374 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Progyny during the 3rd quarter valued at approximately $53,000. CWM LLC lifted its stake in Progyny by 16.1% during the third quarter. CWM LLC now owns 3,490 shares of the company’s stock worth $119,000 after purchasing an additional 483 shares during the last quarter. Duality Advisers LP acquired a new position in Progyny in the third quarter worth $202,000. Finally, Olympiad Research LP bought a new stake in Progyny during the third quarter valued at $222,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on PGNY shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $48.00 price target on shares of Progyny in a report on Wednesday, February 28th. SVB Leerink assumed coverage on Progyny in a report on Monday, February 26th. They set an “outperform” rating and a $49.00 target price for the company. Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a report on Monday, February 26th. Barclays started coverage on Progyny in a research report on Wednesday, January 3rd. They set an “overweight” rating and a $48.00 price objective for the company. Finally, Truist Financial reaffirmed a “buy” rating and issued a $46.00 target price on shares of Progyny in a research report on Wednesday, April 17th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Progyny currently has an average rating of “Buy” and a consensus target price of $48.30.

Progyny Stock Performance

NASDAQ:PGNY opened at $33.06 on Tuesday. Progyny, Inc. has a 1 year low of $29.44 and a 1 year high of $44.95. The business has a fifty day moving average of $36.51 and a 200-day moving average of $35.68. The stock has a market cap of $3.18 billion, a price-to-earnings ratio of 53.32, a PEG ratio of 1.35 and a beta of 1.48.

Progyny (NASDAQ:PGNY) last announced its earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. The firm had revenue of $269.94 million during the quarter, compared to analyst estimates of $274.08 million. Progyny had a net margin of 5.70% and a return on equity of 12.64%. Progyny’s revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.03 EPS. On average, equities research analysts predict that Progyny, Inc. will post 0.7 EPS for the current year.

Insider Buying and Selling

In other Progyny news, Chairman David J. Schlanger sold 20,000 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $38.50, for a total transaction of $770,000.00. Following the completion of the transaction, the chairman now directly owns 86,312 shares of the company’s stock, valued at approximately $3,323,012. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Chairman David J. Schlanger sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $37.52, for a total value of $37,520.00. Following the sale, the chairman now directly owns 83,631 shares in the company, valued at approximately $3,137,835.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman David J. Schlanger sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $38.50, for a total transaction of $770,000.00. Following the sale, the chairman now owns 86,312 shares of the company’s stock, valued at $3,323,012. The disclosure for this sale can be found here. Insiders have sold a total of 120,515 shares of company stock valued at $4,570,131 over the last quarter. Corporate insiders own 12.30% of the company’s stock.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.